Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Cydan
4231
Cydan
Health Care
Technology
Biotechnology
Cydan, an orphan drug accelerator dedicated to creating therapies that improve the lives of patients living with rare genetic diseases.
Suggest edits
Type
B2b
Founded
2012
Raised
$60M
Follow us
Also headquartered in Cambridge
MIT
Raspberry Pi
ARM
Xconomy
Biogen
Money Mover
HubSpot
Formlabs
Akamai
General Catalyst
Companies in the same industry
CareDx
Quantum Biosystems
MyGeneCounsel
Atlantic Healthcare plc
Simris Alg
eXIthera Pharmaceuticals
Entegrion
Aclaris Therapeutics, Inc.
IDEAYA Biosciences
DNAsimple
Alexa global traffic share
Twitter followers
Overview
Funding
3
Add info
Latest funding
Show all
$34,000,000
Venture capital - 2017
Longitude Capital
Pfizer Venture Investments
Lundbeckfonden Ventures
+2
$10,000,000
Venture capital - 2013
Team Size
2
Employees
I work here
Location
Cambridge
,
United States
Headquarters
Explore Cambridge
Xconomy
Cydan, NEA’s Orphan Drug Experiment, Pays Off in $200M Vtesse Deal
Health
$31,000,000
Venture capital (Series A)
businesswire
,
FinSMEs
Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Di...
Xconomy
East Coast Biotech Roundup: Intellia, What’s Hot, Cydan, Fog & More
Science
Health
Xconomy
Cydan, NEA’s Orphan Drug Accelerator, Targets Sickle Cell With Startup Imara
Funding
Health
